-
Jefferies Raises PT On Auxilium Pharmaceuticals To $39
Wednesday, March 23, 2011 - 8:00am | 27Jefferies & Company has raised the price target on Auxilium Pharmaceuticals (NASDAQ: AUXL) from $36 to $39 and maintains its Buy rating.
-
Citi Raises WCRX 2011E EPS Estimate
Wednesday, March 23, 2011 - 7:58am | 112Citi has raised its Warner Chilcott Plc (NASDAQ: WCRX) 2011E EPS by $0.15 to $3.70(+6%) vs. WCRX's revised ‘11E target of $3.60 (+3%) - $3.70 (+5%) & the Street's $3.62(+3%). “WCRX's raised its ‘11E EPS target by $0.15 based on its refinancing of its senior secured credit facilities on more...
-
Citi Maintains Buy Rating On WPI
Wednesday, March 23, 2011 - 7:36am | 100Citi has reiterated the Buy Rating on Watson Pharmaceuticals, Inc. (NYSE: WPI). According to Citi, "Conclusion–WPI received final approval & shipped famciclovir, a generic version of NVS' Famvir, an oral antiviral used to treat herpes. This immediately followed expiration of pediatric...
-
POZEN Announces Licensing Deal with a Division of Johnson & Johnson for Migraine Treatment
Wednesday, March 23, 2011 - 7:32am | 105POZEN Inc. (NASDAQ: POZN) today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson (NYSE: JNJ), for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru. MT 400 is POZEN's proprietary...
-
Oppenheimer Reports On Auxilium Partnership With Asahi Kasei Pharma
Wednesday, March 23, 2011 - 7:01am | 120In a report published by Oppenheimer, Auxilium Pharmaceuticals (NASDAQ: AUXL) announced an outlicensing partnership with Asahi Kasei Pharma to develop and commercialize XIAFLEX in Japan for Dupuytren's contracture and Peyronie's disease. Oppenheimer said that AUXL will receive a $15M up-front...
-
Hot Stock Movers to watch on Wednesday
Tuesday, March 22, 2011 - 4:55pm | 2187( click to enlarge ) Flotek Industries, Inc. (NYSE:FTK) broke out to a new all-time high today accompained by a strong volume suggesting higher levels. The stock has been on a remarkable run since November and it doesn't looks like the trend will change soon. The technical chart still showing...
-
Zings Of The Day (SNY, MRK, AAPL, AMZN)
Tuesday, March 22, 2011 - 3:57pm | 129Sanofi-Aventis SA (NYSE: SNY) and Merck & Co Inc (NYSE: MRK) today announced plans to abandon a joint animal health venture with $5 billion in annual sales, citing the complexity of selling assets to placate regulators. No wonder why Merck has been one of the "dogs" of the Dow. Apple Inc. sued...
-
Lannett Announces Positive Results of Facilities Inspection in Philadelphia
Tuesday, March 22, 2011 - 2:55pm | 70Lannett Company, Inc. (NYSE: LCI) today said that the U.S. Food and Drug Administration (FDA) recently completed an inspection of the company's manufacturing facility in Philadelphia, Pennsylvania and Cody, Wyoming. The inspections concluded with “minor” observations, seven at the company's...
-
ISTA Pharmaceuticals Highlights BEPREVE Clinical Data at the 2011 AAAAI Annual Meeting
Tuesday, March 22, 2011 - 12:49pm | 115ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced additional results from the Company's BEPREVE 1.5% Phase 3 clinical studies in allergic conjunctivitis. These results were presented in poster sessions at the 2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in...
-
ViroPharma Announces Cinryzeman Data Presented at 2011 AAAAI Annual Meeting
Tuesday, March 22, 2011 - 10:21am | 113ViroPharma Incorporated (Nasdaq: VPHM) today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting, March 18 through 22, in San Francisco, CA. Cinryze is the first and only U.S. FDA-approved...
-
Hi-Tech Pharmacal Receives Final FDA Approval for Ranitidine Syrup
Tuesday, March 22, 2011 - 10:04am | 72Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for ranitidine syrup 15mg/mL, the generic for GlaxoSmithKline's Zantac® syrup. Ranitidine syrup had sales of $...
-
Goldman Sachs Maintains Buy on Bristol-Myers Squibb (BMY)
Tuesday, March 22, 2011 - 9:43am | 111Goldman Sachs is out with its report today on Bristol-Myers Squibb (NYSE: BMY), maintaining Buy. In a note to clients, Goldman Sachs writes, "After the market close today, Bristol Myers announced that the long-awaited 024 Phase III trial which studied ipilimumab in first-line metastatic melanoma...
-
Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott
Tuesday, March 22, 2011 - 9:01am | 69Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that it has entered into a collaboration agreement with Abbott (NYSE: ABT) under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate (ADC) technology with antibodies to a single...
-
Mangrove Partners Notes CPEX Stock Trading Above Offer Price
Tuesday, March 22, 2011 - 8:32am | 85Mangrove Partners, owners of 149,373 shares representing approximately 5.71% of the outstanding shares of CPEX Pharmaceuticals, Inc. (Nasdaq: CPEX), questions CPEX's apparent desperate plea to stockholders asking them to support a merger that will pay management over $7 million dollars, or...
-
POZEN Files Motion for Preliminary Injunction in Treximet Patent Litigation
Tuesday, March 22, 2011 - 8:14am | 130POZEN Inc. (NASDAQ: POZN) today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. (Par) from launching a generic version of Treximet. Par, which POZEN believes has 180 days of exclusivity for its generic product as the first company to...